Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E MERTK over exp |
| Therapy | Vemurafenib |
| Indication/Tumor Type | melanoma |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E MERTK over exp | melanoma | resistant | Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, melanoma cell lines harboring BRAF V600E and overexpression of MERTK were resistant to Zelboraf (vemurafenib) in culture (PMID: 29050198). | 29050198 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (29050198) | mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. | Full reference... |